Phio Pharmaceuticals (PHIO) Cash & Equivalents (2016 - 2021)
Historic Cash & Equivalents for Phio Pharmaceuticals (PHIO) over the last 10 years, with Q3 2021 value amounting to $26.5 million.
- Phio Pharmaceuticals' Cash & Equivalents rose 5680.93% to $26.5 million in Q3 2021 from the same period last year, while for Sep 2021 it was $26.5 million, marking a year-over-year increase of 5680.93%. This contributed to the annual value of $14.2 million for FY2020, which is 10395.19% up from last year.
- Phio Pharmaceuticals' Cash & Equivalents amounted to $26.5 million in Q3 2021, which was up 5680.93% from $29.4 million recorded in Q2 2021.
- In the past 5 years, Phio Pharmaceuticals' Cash & Equivalents ranged from a high of $32.7 million in Q1 2021 and a low of $2.7 million during Q1 2018
- Over the past 5 years, Phio Pharmaceuticals' median Cash & Equivalents value was $10.9 million (recorded in 2019), while the average stood at $12.9 million.
- Per our database at Business Quant, Phio Pharmaceuticals' Cash & Equivalents plummeted by 7397.35% in 2018 and then surged by 38177.71% in 2019.
- Phio Pharmaceuticals' Cash & Equivalents (Quarter) stood at $3.6 million in 2017, then skyrocketed by 311.15% to $14.9 million in 2018, then tumbled by 53.22% to $7.0 million in 2019, then skyrocketed by 103.95% to $14.2 million in 2020, then soared by 86.25% to $26.5 million in 2021.
- Its last three reported values are $26.5 million in Q3 2021, $29.4 million for Q2 2021, and $32.7 million during Q1 2021.